Abstract: The present invention provides methods of preventing HIV in a subject, comprising administering to the subject a therapeutically effective amount of bictegravir, or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. Methods of reducing the risk of acquiring HIV (e.g., HIV-1 and/or HIV-2) are also provided.

Abstract: The present invention pertains to a novel protein complex receptor for HIV retroviruses, namely the “V3 loop HIV receptor”, which consists in the association of three proteins named P95/nucleolin, P40/PHAPII and P30/PHAPI. The invention also concerns peptidic or non peptidic molecules having the ability to alter and/or prevent the binding of the said novel HIV receptor to the HIV retrovirus, specifically to the gp120 glycoprotein of said HIV retrovirus. The invention is also directed to pharmaceutical and diagnostic compositions containing an effective amount of the molecules altering and/or preventing the binding of the HIV retrovirus to the novel HIV receptor as well as to therapeutic or diagnostic methods using such pharmaceutical or diagnostic composition.